RSV Adults 01 Kotton 508

CDC ACIP — Vaccine Advisory Committee

Acip

Slides

8

Download PDF ↗ Live URL (may be dead)

Document text

Centers for Disease Control and Prevention
Adult Respiratory Syncytial Virus (RSV) Session
Camille Kotton, MD
Chair, Adult RSV Work Group
Advisory Committee on Immunization Practices (ACIP)
February 23, 2023
2Adult RSV Work Group Membership
ACIP Voting Members
Camille Kotton (Chair)
Keipp Talbot
Sarah Long
Ex Officio Members
Rachel Zhang (FDA)
Judy Beeler (FDA)
Nicholas Geagan (FDA)
Nadine Peart (FDA)Sonnie Kim (NIH/NIAID)
Jeffrey Kelman (CMS)
Valerie Marshal (OIDP)CDC Lead
Michael Melgar
Consultants
Robert Atmar (Baylor College of Medicine)
Helen Chu (University of Washington)
Marie Griffin (Vanderbilt University Medical Center)Cynthia Lucero -Obusan (Veterans Health Administration)
Tracy Ruckwardt (NIH/NIAID)
Liaisons
Kenneth Schmader (AGS)
Shmuel Shoham (ACP)
Gretchen LaSalle (AAFP)April Killikelly (NACI, PHAC)Winnie Su (NACI, PHAC)Michael Hogue (APhA)Katherine Williams (APTR)Ruth Lynfield (NFID)Jennifer Heath (AIM)
3CDC Contributors
Coronavirus and Other Respiratory 
Viruses Division
Fiona Havers 
Meredith McMorrow
Diya SurieJennifer DeCuir
Lauren Roper
Mila PrillAmanda Payne
Natalie Thornburg
Melissa CoughlinJefferson Jones
Katherine Fleming-Dutra
Ismael Ortega SanchezImmunization Safety Office
Anne Hause
David Shay
Christine Olson
Immunization Services Division
Neil Murthy
Patricia Wodi
Debra Blog
Andrew LeidnerJamison Pike
4Recap of RSV session, October 2022
Manufacturer safety and efficacy presentation by GSK regarding 
adjuvanted candidate RSV vaccine for older adults: RSVpreF3
Manufacturer safety and efficacy presentation by Pfizer regarding
bivalent candidate RSV vaccine for older adults: RSVpreF
Work group interim considerations regarding novel RSV vaccines for older adults
5Recent work group discussion
Cost effectiveness of RSV vaccination among U.S. older adults
GRADE and Evidence to Recommendations for GSK adjuvanted RSVpreF3
GRADE and Evidence to Recommendations for Pfizer bivalent RSVpreF
CDC vaccine safety surveillance systems
6Recent work group discussion
Possible policy recommendations* for RSV vaccination of U.S. older adults
–Should RSV vaccines be recommended for U.S. adults aged ≥65 years?
–Should RSV vaccines be recommended for U.S. adults aged ≥60 years?
*FDA has not yet completed review of safety and efficacy data for the GSK adjuvanted RSVpreF3 vaccine and the 
Pfizer bivalent RSVpreF vaccine. ACIP recommendations would be made only if the vaccines are approved and 
licensed by FDA.
7Agenda: Thursday February 23, 2023
Cost effectiveness of RSV vaccination 
a
mong U.S. older adults
Comparison of RSV vaccination economic a
nalyses performed by U. Michigan/CDC, 
GSK, and Pfizer
Evidence to Recommendations framework f
or GSK and Pfizer candidate vaccines
Discussion of vaccine policy optionsD
r. David Hutton
(U. Michigan)
Dr. Ismael Ortega Sanchez 
(CDC)
Dr. Michael Melgar (CDC)
D r. Michael Melgar (CDC)